Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

Share Price is delayed by 15 minutes
Get Live Data
0.19    0.00 (0.00%)
Bid:
0.18
Ask:
0.20
Spread: 0.02 (11.111%)
Market Cap: £8.15m
OBD Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biodyn Share Chart

Holding(s) in Company

10 May 2024 13:11

RNS Number : 0243O
Oxford BioDynamics PLC
10 May 2024
Β 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD5H8572

Issuer Name

OXFORD BIODYNAMICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

Β 

City of registered office (if applicable)

Β 

Country of registered office (if applicable)

Β 

5. Date on which the threshold was crossed or reached

09-May-2024

6. Date on which Issuer notified

10-May-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

1.040500

3.883400

4.923900

15355382

Position of previous notification (if applicable)

1.289400

3.945700

5.235100

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BD5H8572

3244758

1.040500

Sub Total 8.A

3244758

1.040500%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

12110624

3.883400

Sub Total 8.B1

12110624

3.883400%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Β 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Β 

10. In case of proxy voting

Name of the proxy holder

Β 

The number and % of voting rights held

Β 

The date until which the voting rights will be held

Β 

11. Additional Information

Ronnie Sulman01727 895137Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see www.spreadex.com/financials.

12. Date of Completion

10-May-2024

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
HOLEAASEFFFLEFA
Date   Source Headline
15th Apr 20267:00 amRNSBoard Appointment
30th Mar 20264:07 pmRNSHolding(s) in Company
20th Mar 202612:03 pmRNSHolding(s) in Company
3rd Mar 20269:30 amRNS-ROBD to present at PMWC 2026
17th Feb 20267:00 amRNSChange of Nominated Adviser
27th Jan 202612:52 pmRNSHolding(s) in Company
26th Jan 202612:10 pmRNSResult of AGM
26th Jan 20267:00 amRNSBoard Change
22nd Dec 202511:00 amRNSPublication of 2025 Annual Report
22nd Dec 202511:00 amRNSPublication of 2025 Annual Report
16th Dec 20257:00 amRNSPreliminary Results and Notice of AGM
9th Dec 202512:40 pmRNSNotice of Results
3rd Dec 20257:00 amRNSStatement re share price, update on EpiSwitch PSE
25th Nov 20252:05 pmRNSHolding(s) in Company
12th Nov 20257:00 amRNSHolding(s) in Company
11th Nov 20252:12 pmRNSHolding(s) in Company
11th Nov 20252:11 pmRNSHolding(s) in Company
11th Nov 20252:10 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSPDMR Dealing / Grant of Share Options
7th Nov 202511:32 amRNSResult of General Meeting/PDMR Dealings
22nd Oct 20257:00 amRNSFundraising, Posting of Circular & Notice of GM
14th Oct 20257:00 amRNS-ROBD in New Report on NHS Prostate Cancer Screening
8th Oct 20257:00 amRNSOBD and UEA develop test for Chronic Fatigue
10th Sep 20257:00 amRNSHolding(s) in Company
4th Sep 202510:00 amRNS-RStudy confirms clinical utility of EpiSwitch CiRT
13th Aug 20257:00 amRNSCollaboration with Google Cloud
18th Jul 20253:11 pmRNSHolding(s) in Company
17th Jul 20257:01 amRNS-RGenomeWeb to host joint Agilent/OBD presentation
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20255:20 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNS-RPfizer study on EpiSwitch biomarkers
1st Jul 20253:00 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSInterim Results
27th Jun 20251:30 pmRNSHolding(s) in Company
9th May 20257:00 amRNS-ROBD’s Oxford Lab accredited by UKAS
10th Apr 20254:10 pmRNSDirector/PDMR Shareholding
2nd Apr 20257:00 amRNSPDMR Dealing
28th Mar 202510:35 amRNSResult of AGM
17th Mar 20257:00 amRNSBoard Changes
14th Mar 20255:25 pmRNSHolding(s) in Company
13th Mar 20257:00 amRNS-RExpansion of OBD/Bupa UK insurance partnership
5th Mar 20254:00 pmRNSPublication of 2024 Annual Report
3rd Mar 20257:00 amRNSPDMR Dealing / Grant of Share Options
28th Feb 20257:00 amRNSPreliminary Results and Notice of AGM
21st Feb 202510:00 amRNSNotice of Preliminary Results
17th Feb 20251:07 pmRNSHolding(s) in Company
12th Feb 20254:48 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNS-ROBD partners with Regina Maria in Romania
10th Feb 202512:09 pmRNSHolding(s) in Company
6th Feb 20251:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.